drugset / Trial / NCT02052219

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

NCT02052219 ↗

Phase 3 Withdrawn Anthera Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.

Timeline

Start
2014-10
Primary completion
2016-10
Completion
2021-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Blisibimod Peptide — Subcutaneous